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Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid contained in High-density
lipoproteins (HDL) and has drawn considerable attention in the lipoprotein field as
numerous studies have demonstrated its contribution to several functions inherent to
HDL. Some of them are partly and some entirely due to the S1P contained in HDL
(HDL-S1P). Despite the presence of over 1000 different lipids in HDL, S1P stands
out as it possesses its own cell surface receptors through which it exercises key
physiological functions. Most of the S1P in human plasma is associated with HDL,
and the amount of HDL-S1P influences the quality and quantity of HDL-dependent
functions. The main binding partner of S1P in HDL is apolipoprotein M but others
may also exist particularly under conditions of acute S1P elevations. HDL not only
exercise functions through their S1P content but have also an impact on genuine
S1P signaling by influencing S1P bioactivity and receptor presentation. HDL-S1P
content is altered in human diseases such as atherosclerosis, coronary artery disease,
myocardial infarction, renal insufficiency and diabetes mellitus. Low HDL-S1P has also
been linked to impaired HDL functions associated with these disorders. Although the
pathophysiological and molecular reasons for such disease-associated shifts in HDL-
S1P are little understood, there have been successful approaches to circumvent their
adverse implications by pharmacologically increasing HDL-S1P as means to improve
HDL function. This mini-review will cover the current understanding of the contribution
of HDL-S1P to physiological HDL function, its alteration in disease and ways for its
restoration to correct HDL dysfunction.
Keywords: sphingosine-1-phosphate, sphingolipids, High-density lipoproteins, coronary artery disease, HDL
dysfunction, HDL-S1P
Plasma levels ofHigh density lipoprotein cholesterol (HDL-C) are the best knownnegative predictors
of clinical atherosclerosis. Besides their crucial role in reverse cholesterol transport (RCT) HDL
exercise numerous biological functions that are independent of RCT and potentially contributory
to their beneficial effects. Sphingosine-1-phosphate (S1P) is among several of the molecules carried
by HDL that have been implicated as biochemical correlates of these functions particularly because
both alterations ofHDL-S1P content and interference with genuine S1P signaling substantially them.
This mini-review focuses on the current understanding of how HDL-S1P contributes to such HDL
functions and its relevance as a disease marker and possibly therapeutic target in human disorders
characterized by dysfunctional HDL.
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2431
Levkau HDL-S1P as therapeutic option
PHYSIOLOGY OF HDL-S1P: SOURCES,
UPTAKE, AND METABOLISM
The S1P amount in human plasma ranges between 200 and
1000 nM and the majority of it (65–80%) is associated with
the HDL fraction (Okajima, 2002; Zhang et al., 2005; Sattler
et al., 2010) The remainder is contained in other lipoproteins and
associatedwith serumalbumin, respectively. The amphipathic S1P
molecule needs binding to such carriers to be present in biological
fluids. The main plasma apolipoprotein to which S1P physically
binds to is apolipoprotein M (apoM; Christoffersen et al., 2011),
the vast majority of which is contained in HDL (Arkensteijn
et al., 2013). In fact, the presence of apoM determines HDL-
S1P: only the apoM-containing fraction of human HDL carries
S1P, and apoM-deficient mouse HDL contains almost no S1P
(Christoffersen et al., 2011). However, there is no correlation of
apoM and S1P in human plasma (Karuna et al., 2011) or HDL
(own data). On a stoichiometric basis, one in 10 HDL particles
contains S1P (Poti et al., 2014) but only one in 20 contains apoM
(Arkensteijn et al., 2013). In addition, the lipophilic pocket of
apoM that accommodates S1P also serves as a binding domain for
other molecules such as retinol and oxidized phospholipids that
may compete with S1P for binding (Arkensteijn et al., 2013). This
suggests that theremay be othermolecular partners for S1Pwithin
HDLbesides apoMand that their presence and/or associationwith
S1P may depend on the equilibrium with apoM-associated S1P.
Early studies using lipid-depleted charcoal-treated plasma have
demonstrated in cell-based assays that only 2% of the plasma S1P
is biologically active (Murata et al., 2000). This may explain why
luminal endothelial S1P receptors that are constantly exposed to
plasma S1P concentrations 20–100-fold higher than their Kd
values (Mandala et al., 2002) are not desensitized but, instead,
effectively respond to administration of S1P aswell as agonists and
antagonists of its receptors. At the same time, this also suggests
that either only a small part of the S1P contained in HDL is
biologically active or that just part of the HDL-bound pool of
plasma S1P has simultaneous access to S1P receptors. While
the pursuit of the first notion requires clarification of the exact
structural topology and dynamics of S1P as well as its movements
within HDL, the second would be conceptually fulfilled if S1P
required a handoff by a genuine HDL receptor in order to either
engage an adjacent S1P receptor or translocate to the membrane
and glide successively into the binding pocket of the S1P receptor.
There is support in the literature in favor of the scavenger receptor
BI (SR-BI), a genuine HDL receptor, providing such a handoff
particularly because of the considerable overlap between S1P-
dependent and SR-BI-mediated functions of HDL (Yuhanna et al.,
2001; Nofer et al., 2004; Kimura et al., 2006; Tolle et al., 2008).
The physiological sources from which HDL receive their S1P
content are currently unknown. They may be the same as those
giving rise to the overall plasma S1P. As plasma constituents
with the highest affinity for S1P, HDL may represent the primary
binding destination for S1P and/or extract S1P from low-affinity
carriers. This is feasible as HDL are in permanent physical and
metabolic contact with other plasma components including a
variety of lipoproteins which would allow such S1P transfer
to take place. In support of this scenario, the phospholipid
transfer protein, a plasma protein that mediates the exchange
of cholesterol, phospholipids and other amphiphilic molecules
among lipoproteins, has been demonstrated to be involved in
maintaining the S1P content of HDL (Yu et al., 2013). A second
optionwould beHDL acquiring S1P directly from cells and organs
that they are in constant contact with. Indeed, HDL can take
up S1P directly from erythrocytes and do so through physical
contact with the plasma membrane (Bode et al., 2010; Sattler
et al., 2015). Whether this constitutes a passive diffusion process
or involves the biochemically characterized but yet unidentified
erythrocyte ATP/ADP-dependent S1P transporter that transfers
S1P to albumin (Kobayashi et al., 2009) is still unknown. Recently,
a S1P-specific transporter—Spinster homolog 2 (Spns2)—has
been identified as major player in S1P release and secretion
predominantly in lymphatic (Mendoza et al., 2012) but also
vascular endothelial cells (Fukuhara et al., 2012). Endothelial-
specific Spns2-deficient mice have diminished S1P content in
their HDL fraction but this is does not suggest Spns2 transporting
S1P specifically to HDL as it may simply reflect the 50%
reduction in their overall plasma S1P (Fukuhara et al., 2012).
Instead, it nicely exemplifies that general reduction of plasma
S1P goes along with reduction of the S1P amount contained
within the entire HDL fraction. Nevertheless, one study hints at
the possible existence of HDL-specific S1P transporters at least
in astrocytes where the presence/accumulation of S1P in the
extracellular space was coupled to the formation of apolipoprotein
E-containing HDL-like lipoproteins through the ATP-binding
cassette (ABC) transporter ABCA1 (Sato et al., 2007). However,
this observation may be restricted to the brain as plasma S1P is
not reduced inmice deficient forABCA1,ABCA7, orABCC1 (Lee
et al., 2007). Still the idea that S1P incorporation into lipoproteins
can occur at the very early steps of nascent HDL formation where
ABCA1 plays an indispensable role is appealing. Recently, it has
gained support by the observation that hepatocytes—the cells
instrumental for HDL generation—secrete S1P in complex with
apoM, and that hepatocyte-specific apoM-transgenicmice feature
S1P-rich HDL particles and an increased synthesis and release of
S1P (Liu et al., 2013).While the first observationmay be a function
of more apoM being targeted to HDL as their predominant
destination and extracting S1P on itsway there, the second is a hint
that apoM may be, indeed, a genuine S1P carter hauling it across
the hepatocyte membrane and integrating it in complex with itself
into HDL. These observations suggest that S1P incorporation
into HDL may be initiated very early during the HDL generation
process and proceeds throughout HDL maturation.
ESTABLISHED S1P-DEPENDENT
HDL FUNCTIONS
There are many studies that have mapped individual HDL
functions as partially or sometimes completely attributable to
HDL-S1P (for detailed review, see Sattler and Levkau, 2009; Sato
and Okajima, 2011; Poti et al., 2014). Blocking HDL-S1P with
a neutralizing antibody (Sphingomab; Sattler et al., 2015), S1P
removal by delipidation (Murata et al., 2000) and the omission
to substitute S1P during the manufacturing of reconstituted
HDL (Brulhart-Meynet et al., 2015) all result in inferior HDL
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function. Clear-cut proof comes also from experiments where
HDL effects are attenuated by S1P receptor antagonists or in the
respective genetic knockouts or knockdowns. Some of the most
prominent HDL functions shown to depend on HDL-S1P are
listed here: (1) nitric oxide (NO) production by the endothelial
NO synthase (eNOS; Nofer et al., 2004); (2) eNOS/NO-dependent
vasodilatation in explanted arteries and in vivo (Nofer et al., 2004);
(3) inhibition of TNF-induced adhesion molecule expression
in endothelial cells (Kimura et al., 2006); (5) strengthening of
endothelial cell barrier (Wilkerson et al., 2012); (6) endothelial cell
proliferation, survival, tube formation and angiogenesis (Kimura
et al., 2003); (7) induction of long pentraxin 3 (Norata et al.,
2008) and TGFb in endothelial cells (Norata et al., 2005);
(8) migration and angiogenesis promoted by endothelial lipase
(Tatematsu et al., 2013); (9) protection of single cardiomyocytes
and hearts in vivo against ischemic, hypoxic and reperfusion
injury(Theilmeier et al., 2006; Frias et al., 2009a,b; Tao et al.,
2010); (10) inhibition of migration (Tamama et al., 2005; Damirin
et al., 2007), thrombin-induced NADP(H) oxidase activation and
monocyte chemoattractant protein-1 (MCP-1) production (Tolle
et al., 2008) in smooth muscle cells (SMC); (11) desensitization of
guanyl cyclase B (Chrisman et al., 2003) by HDL, HDL-extracted
lipids and authentic S1P, and (12) upregulation of prostacyclin
production and COX2 in SMC (Gonzalez-Diez et al., 2008).
However, the most crucial and physiologically relevant function
of HDL—the participation in reverse cholesterol transport—is
not affected by the presence of S1P within HDL, as measured in
surrogate assays where reconstituted HDL with and without S1P
were similarly effective in stimulating cholesterol efflux (Matsuo
et al., 2007). In summary, the many S1P-attributed functions of
HDL should clearly be considered when overall HDL bioactivity
is being assessed.
Interestingly, there is recent evidence that S1P may exert
different biological functions dependent on whether it acts
in HDL-associated or albumin-associated form. One such
observation has been made in cultured endothelial cells where
HDL-S1P was longer effective at maintaining endothelial barrier
function than albumin-S1P despite the similar half-life, which the
authors contributed to a lower rate of S1P1 internalization and
degradation by HDL-S1P than albumin-S1P (Wilkerson et al.,
2012). In vivo, apoM-deficient mice that virtually lack HDL-S1P
display vascular leakage in the lungs but their plasma S1P is
also reduced by half (Christoffersen et al., 2011). As sphingosine
kinase 1-deficient mice featuring a comparable reduction in
plasma S1P (Allende et al., 2004) also display an increase in
vascular leakiness (Li et al., 2008) there is no evidence for an
exclusive role of HDL-S1P in protecting against it. Furthermore,
many studies have shown that administration of genuine S1P
and S1P receptor agonists protect against endothelial leakage
(McVerry and Garcia, 2005; Wang and Dudek, 2009; Abbasi and
Garcia, 2013; Wilkerson and Argraves, 2014). Nevertheless, a
recent study reiterated the possibility that HDL-S1P may have
unique functions compared to S1P presented by other carriers:
HDL containing apoM-bound S1P but neither apoM-deficient
HDL nor albumin-bound S1P restrained lymphopoiesis and
neuroinflammation (Blaho et al., 2015) although the mechanisms
have remained unclear. They may be manifold such as, e.g.,
differences in S1P presentation mode and the alleged assistance
of HDL receptors in S1P signaling along with differences in
S1P half-life between the different carrier-bound forms (the
metabolism of HDL-associated S1P is fourfold slower than that
of albumin-associated S1P, Kimura et al., 2001). Future work is
needed to delineate the exact mechanisms and mode of action.
ALTERATIONS OF HDL-S1P IN HUMAN
CARDIOVASCULAR, KIDNEY, AND
METABOLIC DISEASES
If the amount of S1P carried by HDL was important for
physiological HDL function in men, human diseases where HDL
function is known to be impaired should be examined for altered
HDL-S1P. HDL dysfunction is a common feature in patients with
atherosclerotic disease, diabetes mellitus, metabolic syndrome
and chronic kidney disease and presents with compromised anti-
oxidative, anti-inflammatory, anti-apoptotic, vasodilative and
cholesterol efflux properties (Kontush and Chapman, 2006;
Barter et al., 2007; deGoma et al., 2008; Besler et al., 2011).
The molecular determinants of HDL dysfunction are still
insufficiently understood and generally sought in the quantitative
and qualitative changes occurring in the HDL proteome and
lipidome including modifications such as oxidation and glycation
(Vaisar et al., 2007; Kontush et al., 2013; Riwanto et al., 2013). Thus
the causal relationships between individual molecular changes
in HDL and their corresponding functional deficits are largely
unknown. Accordingly, any HDL constituent such as S1P that is
identified to participate in HDL function becomes a candidate for
investigation in clinical disease settings (Figure 1).
A number of studies have linked plasma and HDL-S1P to the
incidence of coronary artery disease (CAD): (1) HDL-S1P is lower
in patients with stable CAD than in healthy individuals (Sattler
et al., 2010;Argraves et al., 2011); (2)HDL-S1P correlates inversely
with the occurrence of CAD independently of HDL-C (Argraves
et al., 2011); (3) HDL-S1P correlates negatively with the severity
of coronary atherosclerosis (Sattler et al., 2014), and (4) HDL-
S1P is an independent predictor of coronary in-stent restenosis
(Jing et al., 2015). In patients with acute myocardial infarction
(AMI), both plasma and HDL-S1P levels are increased early after
the onset of symptoms anddecrease thereafter (Sattler et al., 2010).
Transient myocardial ischemia during percutaneous coronary
intervention (PCI) also results in immediate S1P increase in
the coronary sinus that is propagated toward the periphery and
correlates with plasma troponin T (Egom et al., 2013). These
studies imply myocardial injury as a source of acute S1P release.
In contrast, lower plasma S1P concentrations have also been
reported in AMI (Knapp et al., 2013; Polzin et al., 2013) and
modulation of S1P release from platelets has been suggested to
play a role there (Polzin et al., 2013) although HDL-S1P has
not been determined. Among patients with similar AMI severity,
those that develop a stronger inflammatory response also feature
diminished HDL-S1P and a lower propensity of their HDL to
activate eNOS (Gomaraschi et al., 2013). In patients with diabetes
mellitus, HDL-S1P decreases with increasing HbA1c (Tong et al.,
2013), and HDL-S1P is reduced by non-enzymatical glycation
(Tong et al., 2014). This is in apparent contradiction to increased
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2433
Levkau HDL-S1P as therapeutic option
FIGURE 1 | Model of HDL-S1P functions, their impairment in disease and the therapeutic potential they bear by replenishing or increasing the S1P
content of HDL.
HDL-S1P in diabetic patients (Tong et al., 2013) but could be
explained by the performed normalization to the lower plasma
HDL-C of these patients that is common in diabetes and due to
the prevalence of small low-cholesterol HDL particles (Syvanne
et al., 1995). In patients with chronic kidney disease and uremic
syndrome, HDL-S1P (Prufer et al., 2014) andHDL-apoM (Holzer
et al., 2011) are also reduced.
Comparisons among absolute HDL-S1P concentrations in
different studies should be carried out with caution for several
reasons: (1) as serum contains higher S1P concentrations than
plasma HDL isolated from serum (Jing et al., 2015) has higher
S1P levels than that isolated from plasma (Sattler et al., 2010,
2015); (2) HDL-S1P has been often normalized to very different
HDL components in different studies such as total HDL protein
or apolipoprotein AI; it has been also expressed per mol HDL
or even per ml HDL isolate (Kontush et al., 2007; Tong et al.,
2013; Jing et al., 2015; Sattler et al., 2015); (3) although different
methodology of S1P measurement such as LC-MS (Sattler et al.,
2015), commercial ELISA kits (Gomaraschi et al., 2013) and
HPLC (Kontush et al., 2007; Sattler et al., 2010) should be
comparable, they have never been validated side by side in
individual studies; (4) there is considerable variability of HDL-
S1P among HDL subclasses and, accordingly, their different
representation in a certain collective must be considered, and
(5) there is still little known about confounders such as, e.g., the
impact of medication on HDL-S1P.
CONSEQUENCES OF LOW HDL-S1P FOR
HDL FUNCTION AND POTENTIAL
STRATEGIES TO CORRECT HDL
DYSFUNCTION BY INCREASING HDL-S1P
Given the coincidence of low HDL-S1P with HDL dysfunction
in human diseases it is imminent to unravel the molecular
reasons and pursue potential consequences for HDL function.
Conversely, the question should also be addressed whether
HDL dysfunction can be linked to diminished HDL-S1P. If
so, therapeutic options may be considered to either reverse
the biochemical and metabolic changes in HDL resulting in
insufficient S1P content or, as an alternative approach, find
ways to overcome them by pharmacologically increasing HDL-
S1P (Figure 1). Indeed, in CAD and AMI patients, reduced
HDL-S1P has been made responsible for the inferior ability of
their HDL to activate intracellular signaling including eNOS
activation (Gomaraschi et al., 2013; Sattler et al., 2015). In
addition, HDL oxidation in vitro that renders modifications
similar to those observed in CAD (Kontush and Chapman, 2006;
Huang et al., 2014) results in diminished HDL-S1P (Sattler et al.,
2015). However, understanding the biochemical and molecular
determinants of low HDL-S1P in disease may prove particularly
difficult if the aim was to prevent or reverse them to restore
physiological HDL-S1P levels. A more pragmatic approach would
be to try and reinstate normal HDL-S1P content in diseased
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HDL (provided the HDL alterations causing its deficiency did
not preclude it). Actually, a few studies have taken this path
and have raised S1P-HDL to try and improve HDL function.
Early studies in the mouse heart have shown that administration
of human HDL confers cardioprotection against reperfusion
injury through HDL-S1P (Theilmeier et al., 2006). Consecutive
studies using reconstituted HDL have shown that only HDL
manufactured to incorporate S1P are cardioprotective (Brulhart-
Meynet et al., 2015). To increase regular HDL-S1P levels, human
HDL have been incubated with sphingosine-loaded erythrocytes
as physiological S1P donors or with purified S1P and were found
to take up large amounts of S1P exceeding those carried within
by 10–20-fold (Bode et al., 2010; Sattler et al., 2015). Not only
purified but also HDL residing inherently in human plasma
effectively acquires S1P from erythrocytes, and C17-S1P injected
intravenously inmice in the form of C17-S1P-loaded erythrocytes
relocates immediately and almost completely to HDL (Sattler
et al., 2015). Similar observations have been made in humans
where erythrocyte transfusion resulted in increased plasma and
HDL-S1P (Selim et al., 2011). Such pharmacological increases
in HDL-S1P have a clear impact on HDL function as S1P-
loadedHDL showed enhanced activation of intracellular signaling
pathways including eNOS activation in human endothelial cells
and a superior vasodilation in isolated arteries (Sattler et al., 2015).
Interestingly, not only healthy but also oxidized and glycated
HDL, respectively, take up S1P (Tong et al., 2014; Sattler et al.,
2015). Although not as efficiently as healthy HDL, oxidized HDL
still take up considerable amounts of S1P thereby reaching even
higher S1P content than that of healthy HDL (Sattler et al.,
2015). This occurs independently of apoM as apoM was almost
undetectable in oxidized HDL despite considerable S1P uptake,
and murine apoM-deficient HDL was unimpaired in taking up
S1P (Sattler et al., 2015). Remarkably, HDL isolated from patients
with CAD take up S1P as efficiently and to the same extent as
healthy HDL (Sattler et al., 2015). Most importantly, however, S1P
supplementation is accompanied by the complete restoration of
previously impaired functions of CAD-HDL: S1P-loaded CAD-
HDL were as efficient as healthy HDL in activating eNOS and
mediating vasorelaxation (Sattler et al., 2015). Similarly, S1P-
supplemented glycated HDL re-obtain their ability to induce
cyclooxygenase-2 (Tong et al., 2014).
Administration of reconstituted HDL, HDL mimetics and
apolipoprotein A-I peptides has been one of the many approaches
to raise HDL in attempt to treat cardiovascular disease (Kingwell
et al., 2014). Several potentially beneficial effects have been
observed in experimental models of disease and encouraging
results reported for some of these preparations, respectively,
e.g., in acute coronary syndrome where atherosclerotic plaque
volume was reduced and inflammation ameliorated (Reddy et al.,
2014; Remaley et al., 2014; White et al., 2014). Interestingly,
among the functional effects caused by HDL administration are
several that have been attributed at least in part to HDL-S1P
such as arterial vasodilation. Indeed, impaired flow-mediated
vasodilation (FMD) in CAD is associated with low HDL-C
(Li et al., 2000) and can be substantially improved by the
administration of reconstituted HDL (Spieker et al., 2002).
Considering the lowHDL-S1P in CAD and the extremely efficient
ability ofHDL to take up S1P, it is plausible to assume that the acute
raise of plasma HDL has lead to an increase in the overall pool of
HDL-S1P which could have promoted the S1P-conveyed part of
HDL-mediated FMD. Such observations may extend to any of the
functionally overlapping effects of administered HDL and those
known for HDL-S1P. Accordingly, provided that such indirect
increase in HDL-S1P following HDL administration contributes
to the observed effects, a more direct intervention aimed at
specifically loading S1P onto HDL prior to administration may
prove additionally helpful in tackling HDL dysfunction.
Future Questions
High-density lipoproteins come in a variety of subclasses and
particle sizes and are subject to constant dynamic remodeling
through their interaction with plasma constituents, tissues and
cells. At the same time, HDL are subject to a plethora of
pathophysiologicalmodifications in cardiovascular andmetabolic
diseases. There is sufficient evidence that many of these processes
are bound to have an impact on the amounts of S1P that HDL are
exposed to, accumulate and transport, and thus influence HDL-
S1P-mediated functions. Understanding the molecular events
that determine these processes inside and outside of HDL is
of major importance. It is also imminent to comprehend how
exactly HDL acquire S1P from their surroundings and present it
to S1P receptors for signaling. The existence of HDL receptors
makes it plausible that signaling by HDL-associated S1P might be
prevalent at sites where HDL engages its own receptors and would
thus distinguish such targeted S1P signaling from the ubiquitous
one ensuing from S1P in its albumin-bound form. In summary,
understanding the exact regulation and contribution of HDL-S1P
to key HDL functions would allow the design of strategies that
employ S1P to enhance the effectiveness of HDL-based therapies.
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